Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
4G7xH22
- Development stage
- Phase 1
- Lead developer
- National Cancer Institute
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
4G7xH22 is a bispecific antibody developed by the National Cancer Institute for the treatment of B-cell malignancies, specifically refractory or relapsed non-Hodgkin's lymphoma and chronic lymphocytic leukemia. This investigational immunotherapeutic is designed to target two antigens simultaneously—CD19 and CD30—on malignant B cells, thereby enhancing immune-mediated cytotoxicity against these cancer cells. The drug leverages dual specificity to improve anti-tumor activity compared to monospecific antibodies, primarily through mechanisms such as antibody-dependent cellular cytotoxicity (ADCC). Clinical development reached Phase 1 but was discontinued[1][2][3][5].
- Other names
- bispecific antibody 4G7xH22
02
Targets
CD19 (B lymphocyte antigen CD19)CD30 (CD30 antigen)
Beyond the preview
Go deeper on 4G7xH22.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 4G7xH22.